Table 3. Comparison of the response to transarterial chemoembolization (TACE) and systemic pharmacological treatment in the elderly vs. young patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA).

Tumor	Treatment	Response	Ref.
HCC	Sorafenib	Comparable survival benefits and safety	[120, 121]
	Lenvatinib	Comparable survival benefits and safety	[122]
	Regorafenib	Similar survival benefit in HCC patients progressing on sorafenib treatment	[124]
	Cabozantinib	Similar OS, PFS and middle-term outcome	[124, 126]
	Ramucirumab	Similar OS and safety	[127]
	Nivolumab	Similar OS	[128]
	Pembrolizumab	Similar OS and PFS	[129]
	Atezolizumab plus Bevacizumab	Similar OS, PFS and tolerability	[130]
	TACE	Good efficacy and tolerance even in >85	[114, 115]
iCCA	Gem/Cis	Similar OS	[133]
	Capecitabine	Similar effects when used after surgery	[134]
	Lenvatinib	Similar safety	[135]
	Pemigatinib	Better PFS	[136]
	Ivosidenib	Similar drug disposition	[137]
	TACE	Good efficacy and tolerance	[117]

Gem/Cis, Gemcitabine/Cisplatin; OS, overall survival; PFS, progression-free survival; TACE, trans-arterial chemoembolization.